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ABSTRACT 
Upon stimulation with Th1 cytokines or bacterial 
lipopolysaccharides, resting macrophages shift 
their phenotype towards a pro-inflammatory state 
as part of the innate immune response. LPS 
activated macrophages undergo profound 
metabolic changes to adapt to these new 
physiological requirements. One key step to 
mediate this metabolic adaptation is the 
stabilization of Hif1α, which leads to increased 
glycolysis and lactate release, as well as decreased 
oxygen consumption. Hif1 abundance can result in 
pyruvate dehydrogenase kinase 1 (Pdk1) 
induction, which inhibits pyruvate dehydrogenase 
(Pdh) via phosphorylation. Therefore, it has been 
speculated that pyruvate oxidation through Pdh is 
decreased in pro-inflammatory macrophages. 
However, to answer this open question, an in-
depth analysis of this metabolic branching point 
was so far lacking. In this work, we applied stable 
isotope-assisted metabolomics techniques and 
demonstrate that pyruvate oxidation is maintained 
in mature pro-inflammatory macrophages. 
Glucose derived pyruvate is oxidized via Pdh to 
generate citrate in the mitochondria. Citrate is used 
for the synthesis of the antimicrobial metabolite 
itaconate and for lipogenesis. An increased 
demand for these metabolites decreases citrate 
oxidation through the TCA cycle, while increased 
glutamine uptake serves to replenish the TCA 
cycle. Furthermore, we found that the Pdh flux is 
maintained by unchanged Pdk1 abundance, despite 
the presence of Hif1. By pharmacological 
intervention, we demonstrate that the Pdh flux is 
an important node for M(LPS) macrophage 
activation. Therefore, Pdh represents a metabolic 
intervention point that might become a research 
target for translational medicine to treat chronic 
inflammatory diseases.  
 
INTRODUCTION 
Macrophages are innate immune cells that 
differentiate from monocytes, which circulate in 
the blood stream. Upon differentiation, they 
invade the surrounding tissue and become resident 
macrophages (1). Macrophages can be activated 
by cytokines or toll-like receptor (TLR) agonists, 
e.g. lipopolysaccharide (LPS). In very general 
terms, macrophage activation can result in rather 
pro-inflammatory responses, serving as host 
defense mechanisms or in wound healing 
responses, aiding in tissue repair and remodelling. 
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However, depending on the type of activation very 
different subtypes of activation occur (2). Upon 
activation with LPS (M(LPS)) or the cytokine 
interferone-γ (M(Infγ)), macrophages undergo 
profound metabolic reprogramming, necessary to 
activate cellular defence mechanisms as well as to 
cope with different micro-environments in the 
inflamed tissue (3). A marker for pro-
inflammatory activation is high expression of Irg1 
(4,5). We recently showed that Irg1 codes for the 
enzyme cis-aconitate decarboxylase (Irg1/Cad) 
that catalyzes the synthesis of the antimicrobial 
metabolite itaconate from cis-aconitate (6). 
Therefore, metabolic reprogramming due to these 
adaptations could affect the availability of 
substrate needed for the synthesis of itaconate 
during host defense.  
The reprogramming during macrophage activation 
shows overlapping features with cancer cells: both 
have increased glycolytic rates and increased 
lactate release, known as aerobic glycolysis or the 
Warburg effect (7,8). Increased glycolytic rates are 
observed in any cell type that exceeds the energy 
demand derived from oxidative phosphorylation 
(9). In macrophages, it has been revealed that this 
metabolic rewiring is mediated by stabilization of 
Hif1α (10). A well-described Hif1 target is 
Pyruvate dehydrogenase kinase 1 (Pdk1), an 
inhibitor of Pyruvate dehydrogenase (Pdh) (11). 
When Hif1 is stabilized, the Pdh flux can be 
inhibited by Pdk1 mediated phosphorylation, 
resulting in decreased pyruvate derived acetyl-
CoA levels. In this case, reductive carboxylation 
of α–ketoglutarate (aKG) increases, to provide 
sufficient acetyl-CoA for lipogenesis, needed for 
cell proliferation (12–15). Increased glycolytic 
rates, decreased Pdh flux and increased reductive 
carboxylation can also be induced in any cell type 
when oxygen tension is decreased or when 
oxidative phosphorylation (OxPhos) is impaired. 
In this case, NADH oxidation is compromised and 
citrate levels decrease. This decrease in citrate is 
linked to an increase in NADH thermodynamically 
promotes the metabolic adaptation to hypoxia by 
increasing reductive carboxylation of aKG 
(13,16,17). However, it is currently unclear if this 
full panel of metabolic consequences upon Hif1 
stabilization is also true for pro-inflammatory 
macrophages. While it has been demonstrated that 
Hif1α can be stabilized and activated by cytokines, 
e.g. Tnfα and Il1β (18,19), the detailed metabolic 
consequences are still uncertain.  
Hif1 can bind to the promoter of the Tlr4 gene, 
thereby acting through a positive feedback loop on 
the Tlr4 defense axis (20). Reactive oxygen 
species were shown to inhibit proteasomal 
degradation of Hif1α (21) and recently, increased 
succinate levels in pro-inflammatory macrophages 
have also been described to stabilize Hif1α, by 
inhibiting prolyl hydroxylase mediated 
hydroxylation of Hif1α (10). 
In this study, we asked whether the stabilization of 
Hif1α in M(LPS) macrophages alters TCA cycle 
fluxes similarly to hypoxic cells. We show that 
LPS activated macrophages exhibit a metabolic 
adaptation with overlapping features to hypoxic 
cells, but also distinct differences, resulting in a 
unique LPS-specific metabolic signature. The 
most striking difference to hypoxic cells with 
stabilized Hif1α is that there is no decrease in 
relative glucose flux through Pdh, and no increase 
in reductive carboxylation of aKG. The sustained 
Pdh flux provides sufficient acetyl-coA for citrate 
production, which keeps the rate of reductive 
carboxylation of aKG at a low level, as well as 
providing citrate that is needed for the synthesis of 
fatty acids and itaconate. Upon LPS stimulation, 
high Pdh activity is maintained by a repression of 
Pdk1. As a result Pdh phosphorlylation on ser232 
and ser293 remains at low level. Finally, we 
demonstrate that the Pdh flux is indeed important 
to sustain M(LPS) activation in macrophages.  
 
EXPERIMENTAL PROCEDURES 
Chemicals 
UK5099 (Sigma, PZ0160) was first diluted in 
DMSO and further diluted in medium to a working 
stock concentration of 10 mM and then spiked into 
the wells of the culture dish to a final 
concentration of 100 µM. The final concentration 
of DMSO did not exceed 1%; LPS (E.Coli, Sigma 
L6529) was prepared as a working stock of 1 
µg/ml in glucose and glutamine free DMEM, 
spiked 1:100 into the wells of the culture dish for a 
final concentration of 10 ng/ml. Cells were 
stimulated for 6 hours; Interferon g (mouse) 
(E.Coli, Sigma I4777) was prepared as a working 
stock of 5 mg/ml in glucose and glutamine free 
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DMEM, spiked 1:100 into the wells of the culture 
dish for a final concentration of 50 ng/ml. Cells 
were stimulated for 6 hours. 
Stable isotope tracing 
13C stable isotope tracers were obtained from 
Eurisotop; Glucose: CLM-1396, Glutamine: 
CLM-1822-H. The tracer medium was prepared in 
DMEM without glucose and glutamine. 13C 
glucose (final 25mM) and 12C glutamine (final 
4mM) (or vice versa) was added to the medium, 
pH was set to 7.3, 10 % FBS and 1% P/S were 
added and finally, the medium was sterile filtered. 
Tracer medium was prepared in advance and 
incubated in the hypoxia chamber overnight to 
remove excessive oxygen from the medium (only 
for hypoxia conditions). The next morning, 
medium was replaced by tracer medium and cells 
were incubated for 24h with the tracer medium to 
reach isotopic steady state. LPS was added after 
24h and left on the cells for an additional 6h prior 
to extraction. For further information regarding 
stable-isotope assisted metabolomics see also 
(22,23). 
Cell culture  
RAW 264.7 cells (ATCC® TIB-71™) were 
obtained from ATCC and were cultivated 
according to the manufacturers instructions. 
Briefly, cells were kept in DMEM5796 with 
10%FBS and 1% P/S at 37°C and 5% CO2 under 
atmospheric oxygen concentrations. In the case of 
hypoxia, cells were cultivated in an incubator at 
37°C and 5% CO2 located in a closed hypoxia 
chamber with an oxygen concentration of 2%. 
Cells were simultaneously seeded in the afternoon 
at a density of 150.000 cells per well in 12-well 
plates (Thermo Scientific, Nunc Multidish 12 
Nunclon Delta Si) and then either incubated either 
at 21% or 2% O2 overnight. The next day, medium 
was replaced. In the case of hypoxia, medium was 
already incubated in the hypoxia chamber over 
night to remove excessive oxygen from the 
medium. For comparison reasons, medium for 
normoxic conditions was also prepared the day 
before and incubated in a similar way under 
atmospheric oxygen conditions. For LPS 
activation, LPS was added 18h after medium 
replacement. 24h afer medium replacement cells 
were harvested. 
Viability Assay 
To assess cell viability, cells were transferred into 
tubes and analysed using a Vi-Cell(TM) XR 
(Beckman Coulter) automated cell counter. To 
determine viability, cells were incubated with 
Trypan blue and number of stained cells was 
determined. 
cDNA synthesis and gene expression analysis 
cDNA synthesis and qPCR was performed as 
previously described (Michelucci et al., 2013). 
Briefly, RNA was isolated from the interphase 
after extraction of metabolites, using the Qiagen 
RNAeasy Mini Kit. 0.5 -1 µg RNA was used for 
cDNA synthesis using SuperScript III 
(Invitrogen), following the manufacturer's 
instructions. qPCR was performed using iQ SYBR 
Green Supermix (Bio-Rad) as per manufacturer's 
instructions. PCR was carried out on a Light 
Cycler 480 (Roche). Data analysis was performed 
using the Roche analysis software according to 
manufacturer's instructions. Gene expression was 
normalized to the housekeeping gene L27. For 
primer sequences, see Table 1. 
Extraction of intracellular metabolites 
Extraction was according to (24). Briefly, cells 
were cultivated in 12-well plates and washed with 
1 ml of 0.9% NaCl and quenched with 0.2 ml -20 
°C methanol. After adding an equal volume of 4 
°C cold water, cells were collected with a cell 
scraper and transferred to tubes containing 0.2 ml -
20 °C chloroform. The extracts were shaken at 
1400 rpm for 20 min at 4 °C (Thermomixer 
Eppendorf) and centrifuged at 16,000×g for 5 min 
at 4 °C. 0.2 ml of the upper aqueous phase was 
collected in specific glass vials with micro inserts 
and evaporated under vacuum at -4°C using a 
refrigerated CentriVap Concentrator (Labconco). 
Gas Chromatography-Mass Spectrometry  
Metabolite derivatization was performed using a 
Gerstel MPS. Dried polar metabolites were 
dissolved in 15 µl of 2% methoxyamine 
hydrochloride in pyridine at 40 °C under shaking. 
After 60 min, an equal volume of MTBSTFA was 
added and held for 60 min at 40°C. 1 µl of sample 
was injected into an SSL injector at 270°C in 
splitless mode. GC/MS analysis was performed 
using an Agilent 7890A GC equipped with a 30m 
DB-35MS + 5m Duraguard capillary column. 
Helium was used as carrier gas at a flow rate of 
1.0 ml/min. The GC oven temperature was held at 
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100 °C for 2 min and increased to 300 °C at 10 
°C/min. After 3 min, the temperature was 
increased to 325 °C. The GC was connected to an 
Agilent 5975C inert XL MSD, operating under 
electron ionization at 70 eV. The MS source was 
held at 230 °C and the quadrupole at 150 °C. The 
MS was operated in selected ion monitoring 
(SIM). The total run time of one sample was 25.00 
min. All GC/MS chromatograms were processed 
by using MetaboliteDetector software (25). MIDs 
were determined and corrected for natural isotope 
abundance using MetaboliteDetector. 
Measurement of glucose and lactate intensities 
was performed by derivatization with an equal 
volume of MSTFA (instead of MTBSTFA) and 
held for 30 min at 40 °C under continuous 
shaking. 1 µl sample was injected into an SSL 
injector at 270°C in split 10 mode. GC oven 
temperature was held at 90°C for 1 min and 
increased to 300 °C at 15 °C/min for 8 min to 
320°C. The total run time of one sample was 24.3 
min. For absolute quantification of glucose and 
lactate, a dilution series of a standard mix was 
included in the sequence and measured in 
triplicates. For normalization, we used [U-
13C]glucose and [U-13C]lactate as internal 
standards (in this case, medium samples contained 
only 12C carbon sources).  
Quantification of Amino Acids 
Quantification of amino acids was performed on 
an Agilent 1100 HPLC System equipped with a 
Diode Array Detector. Separation was carried out 
on a ZORBAX Amino Acid Analysis Column 
(150 x 4.6 mm, 5µm) with a preceding ZORBAX 
Amino Acid Analysis Guard Cartridge (Agilent 
Technologies, Santa Clara, CA, USA) at 40°C in 
gradient mode (see Table 1). The eluents used 
were 40 mM Na2HPO4 (pH 7.8, eluent A) and a 
mixture of Acetonitrile, Methanol and Water 
(45:45:10, eluent B). 0.02% sodium azide was 
added to eluent A to prevent microbial growth. 
Primary amines were automatically derivatized 
with ortho-phthalaldehyde (OPA) in borate buffer 
(0.4 N in water, pH 10.2) and diluted in eluent A 
prior to injection. The resulting OPA-derivatives 
were subsequently detected at 338 nm (10 nm 
bandwidth – reference wavelength: 390 nm, 20 nm 
bandwidth). All medium samples were diluted 1:1 
with the internal standard L-2-aminobutyric acid 
(final concentration: 300 µM) to correct for 
deviations resulting from the derivatization-
process. External calibration standards as well as 
reference media with known concentrations were 
measured with every run to determine sample 
concentrations and ensure stability of the analysis. 
Gradient profile: 1.9 min: 0 % eluent B; 18.1 min: 
57 % eluent B; 18.6 min: 100 % eluent B; 22.3 
min: 100 % eluent B; 23.2 min: 0 % eluent B; 26 
min: 0% eluent B.  
Western Blot 
For preparation of whole cell extract, 1x106 cells 
were harvested, washed with ice cold 1x 
phosphate buffered saline (PBS) (Invitrogen/Life 
Technologies Europe BV Belgium), lyzed in 1x 
M-PER®, Mammalian Protein Extraction Reagent 
(Thermo Scientific, Belgium) completed with 1x 
protease inhibitor cocktail (Complete®, Roche, 
Luxembourg) and further processed according to 
manufactures instructions. A Nanodrop analyzer 
was used to measure the protein 
concentration. Proteins were separated by size 
using SDS-PAGE (12%) and transferred to an 
Immobilon-FL PVDF membrane (Merck 
Millipore) using the Mini-PROTEAN Tetra Cell 
and PowerPac Basic Power Supply (Bio-Rad, 
Belgium). The membrane was blocked in 5 % 
non-fat milk powder in PBS-Tween for 1 h at 
room temperature or over night at 4°C. Used 
antibodies: Anti-Irg1 (Sigma, hpa040143) 1:750 in 
PBS-T 5% non-fat milk powder for 1 h at room 
temperature; Anti-PDK1 (rabbit):  (Enzo #ADI-
KAP-PK112) 1:3000 in TBST 5% BSA, o/n at 
4°C; Anti-PDH-E1alpha (rabbit) (pSer232) 
(Millipore #AP1063) 1:1000 in TBST 5% BSA, 
o/n at 4°C; Anti-PDH-E1alpha (rabbit) (pSer300) 
(Millipore #ABS194) 1:1000 in TBST 5% BSA, 
o/n at 4°C; Anti-PDH-E1alpha (rabbit) (pSer293) 
(Millipore #ABS204) 1:10000 in TBST 5% BSA, 
o/n at 4°C; Anti-alpha-tubulin (mouse) 1:5000 in 
TBST 5% BSA, o/n at 4°C; anti-rabbit-HRP 
1:5000 in TBST 5% Skim Milk (Cell signalling); 
anti-mouse-HRP 1:5000 in TBST 5% Skim Milk 
(Cell signalling). Visualization was done using the 
ECL Plus Western Blotting Detection System Kit 
(GE Healthcare, Netherlands). Signals were 
detected using the LI-COR System. Quantification 
of band intensities was done using the 
ImageStudioLite Software package. 
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Cell imaging and data analysis 
Phase contrat images were acquired using a 10X 
objective on a Nikon Ti Eclipse inverted 
microscope with motorized stage (Nikon 
Corporation, Tokyo, Japan) enclosed in a bench 
top incubator. Automatic microscope control, 
stage programming and acquisition were done 
using the OptoMorph version of MetaMorph 
7.8.10 (Cairn Research, Kent, UK). LPS treated 
and untreated RAW 264.7 cells growing in 12-
well Nunc plates (50.000 cells per well) were 
imaged in positive phase contrast. Nine adjacent 
but non-overlapping images were automatically 
acquired in a 3x3 grid around the center of each 
well. The entire imaging experiment was 
performed twice, resulting in 36 images acquired 
per condition. One out-of-focus image and five 
containing cell aggregates were excluded from 
further analysis. Surfaces of strongly attached cells 
were estimated by thresholding in ImageJ 2.0.0-rc-
31/1.49v using the IJ_IsoData algorithm. 
Congruence of thresholding results with cell 
contours was verified by visual inspection. Cell 
sizes were calculated using the particle analysis 
tool, allowing for areas from 50 to 5000 px and 
excluding particles on the image edges. Average 
sizes were reported for each image. Halo and 
contrast effects resulting from the phase-contrast 
imaging were analyzed to discriminate between 
strongly and weakly attached cells. Strongly 
attached cells appeared darker than background 
with weak halo, while weakly attached cells 
appeared brighter than background with strong 
halo. Histograms of pixel intensities of the entire 
field of view were analyzed using custom software 
written in MATLAB R2014b. First, the intensity 
peak corresponding to the background signal (cell-
free surface) was identified and approximated by a 
Gaussian function. The approximated peak was 
subtracted from the original histogram and the 
weighted sum of intensities below (dark) and 
above (bright) the background peak was 
calculated, respectively. The ratio of dark-to-
bright values informs on the ratio of strongly-to-
weakly attached cells. Renormalization of this 
ratio by values obtained for individual strongly 
and weakly attached cells yielded an adhesion 
index with values from 0 (no cells attached) to 1 
(all cells attached). 
Statistical analyses 
To analyze a significant difference between two 
groups, unpaired Welch's t-Test was applied. p – 
values are indicated in each panel (* p < 0.01; or 
as indicated) and was considered as significant 
different with a p – value < 0.05. The number of 
independent replicates is indicated in the figure 
legends. Each experiment was at least performed 
three times with cells of a different passage. Each 
individual experiment consisted of three wells per 
condition. 
 
RESULTS 
M(LPS) macrophages show a distinct 
metabolite signature 
The macrophage environment is likely to be 
hypoxic, as these cells infiltrate hypoxic tissues 
such as tumors, wounded regions or sites of 
inflammation. At the site of inflammation, 
different oxygen tensions result from increased 
oxygen demand as well as swelling or vascular 
damage (26,27). To physiologically meet these 
challenging conditions, macrophages are well 
adapted to hypoxia by their ability to adjust their 
gene expression profile and increase glycolytic 
activity (28). To study if the activation of 
macrophages reprograms metabolism to a 
hypoxia-like phenotype, we cultivated the murine 
macrophage cell line RAW 264.7 under normoxia 
(21% oxygen) and hypoxia (2%) and activated it 
with LPS for 6h. We selected this time point, 
because it reflects the highest expression level of 
Irg1, the gene that codes for the enzyme which 
catalysis the synthesis itaconate (6). 
We analysed intracellular metabolite levels and 
revealed that LPS stimulation resulted in increased 
levels of itaconate, succinate and lactate under 
normoxia (Figure 1A-C). These three metabolites 
are marker metabolites for M(LPS) activation, 
demonstrating a clear pro-inflammatory activation 
(6,10,29,30). Moreover, we observed increased 
levels of the TCA cycle associated metabolites 
malate and glutamate, whereas aspartate and 
citrate levels remained unchanged (Figure 1D-G). 
The amino acids glycine, serine and alanine were 
also elevated upon LPS stimulation (Figure 1H-J). 
Compared to normoxia, LPS treatment of hypoxic 
cells was unable to induce similar itaconate and 
succinate levels (Figure 1A and B). As expected, 
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lactate levels further increased upon hypoxia as a 
result of reduced respiration and concomitant 
increased glycolysis, known as the Pasteur Effect.  
Non-activated, hypoxic cells exhibited decreased 
levels of the TCA cycle associated metabolites 
malate, aspartate, glutamate and citrate. However, 
LPS stimulation under hypoxia resulted in 
increased levels of malate, aspartate and glutamate 
but not citrate (Figure 1D-G). The amino acids, 
glycine and serine were unchanged between 
hypoxia and normoxia. Upon LPS activation of 
hypoxic cells, serine and alanine were increased 
(Figure 1H-J). Interestingly, we also observed a 
trend of increased levels of the branched chain 
amino acids isoleucine, leucine and valine under 
hypoxia for both non-stimulated and LPS 
stimulated conditions (Figure 1K; p-value > 0.05).   
We concluded from these results that LPS affects 
the metabolite profile of macrophages independent 
of the oxygen supply and that this profile is clearly 
different to a pure hypoxic profile. Intriguingly, 
we observed decreased abundance of the 
antimicrobial metabolite itaconate under oxygen 
limiting conditions, which could have direct 
effects on the immune response in tissues with low 
oxygen tension.  
 
Decreased itaconate levels under hypoxia are 
not the result of decreased Irg1 expression or 
lower Irg1/Cad protein abundance 
To investigate if the reduced levels of itaconate are 
caused by transcriptional repression, post-
transcriptional regulation or post-translational 
regulation, we analyzed gene expression and 
protein levels of the catalyzing enzyme Irg1/Cad. 
We found that hypoxia does not significantly 
reduce the gene expression level or the protein 
abundance of Irg1/Cad, indicating a regulation at 
the post-translational level or a result of decreased 
substrate concentrations (Figure 2A and B). To 
confirm LPS activation of macrophages, we 
analyzed gene expression of the pro-inflammatory 
marker genes Tnfα, iNos and Il1β (Figure 2C-E). 
We found clear up-regulation under both oxygen 
conditions when the cells were treated with LPS. 
However, hypoxia resulted in a 20 % reduction of 
Tnfα expression and approximately three-fold 
higher expression of Il1β and iNos.  
It has been reported in several recent publications 
that Hif1α gets stabilized in M(LPS) macrophages 
compared to resting macrophages (10,21,29,31). 
Therefore, we also analyzed gene expression of 
Hif1α, and we observed increased expression of 
Hif1α in response to LPS treatment under hypoxia 
(Figure 2F), indicating that Hif1α stabilization in 
hypoxic M(LPS) macrophages can be a combined 
effect of increased transcriptional expression and 
post-translational stabilization. Under normoxia, 
no difference in Hif1α expression was detected.  
Based on these results we conclude that the 
reduction of itaconate under hypoxia is mostly a 
result of post-translational effects such as altered 
metabolic fluxes, either due to an enzyme 
modification that regulates its activity or by 
changing substrate concentrations. To that end, we 
were interested to compare cellular flux changes 
with LPS activation between hypoxia and 
normoxia. 
 
LPS activation promotes pyruvate oxidation via 
Pdh by preventing Pdk1 expression 
To monitor intracellular glucose derived fluxes in 
M(LPS) macrophages, we incubated RAW264 
cells for 24h in the presence of uniformly labeled 
[U-13C]glucose to reach isotopic steady state 
conditions. During these 24h, labeled glucose is 
metabolised within the cells and is incorporated in 
cellular metabolites downstream of glucose. To 
obtain the specific labeling patterns, intracellular 
metabolites were extracted and analyzed with gas 
chromatography/mass spectrometry to determine 
mass isotopomer distributions (MIDs; corrected 
for natural isotope abundance), which reflect 
relative metabolic fluxes (Figure 3A for atom 
transitions) (22,23).  
As expected, stable isotope labeling revealed that 
hypoxia resulted in decreased pyruvate flux 
through Pdh, illustrated by decreased M2 citrate 
isotopologues (Figure 3B). Concomitant with 
decreasing citrate M2 isotopologues under 
hypoxia, we observed increased abundance of 
citrate M0 isotopologues, representing citrate 
molecules derived from carbon sources other than 
glucose (Figure 3B). This decrease is a result of 
Hif1α stabilization and Pdk1 induction, which 
inhibits Pdh by phosphorylation (32,33). 
Decreased pyruvate oxidation under hypoxia 
promotes decreasing downstream substrate levels, 
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most probably resulting in the observed decreased 
itaconate levels (Figure 1A). However, Hif1α has 
also been shown to be stabilized in M(LPS) 
macrophages under normoxic conditions (10,29). 
Therefore, it is speculated that pyruvate oxidation 
through Pdh is decreased in M(LPS) macrophages, 
a similar phenotype to cancer cells with stabilized 
Hif1α (3,34). However, we did not observe 
decreased citrate M2 isotopologues in normoxic 
M(LPS) macrophages, raising the question if Pdh 
is inhibited under these conditions.  
To analyse regulation of Pdk1 in more detail we 
investigated gene expression and protein 
abundance of Pdk1 and phosphorylation status of 
Pdh (Figure 3C-H). In line with current 
knowledge, hypoxia mediated stabilization of 
Hif1α resulted in increased Pdk1 expression 
(Figure 3C), which complements our observation 
of hypoxia-dependent, decreased glucose flux to 
citrate (Figure 3B). Intriguingly, we observed that 
LPS stimulation resulted in a drastic reduction of 
Pdk1 expression at both normoxia and hypoxia, 
indicating that Pdk1 mediated inhibition of Pdh is 
reduced in M(LPS) macrophages (Figure 3C). 
Moreover, analysis of Pdk1 protein abundance 
revealed similar Pdk1 levels in non-activated or 
M(LPS) activated macrophages. Only in hypoxia 
did we observe a significant increase of Pdk1 
abundance (Figure 3D,E). To investigate if the low 
levels of Pdk1 have an effect on Pdh, we analyzed 
phosphorylation of Pdh on serine 232, 293 and 
300 (Figure 3 D, F-H). Phosphorylation of these 
residues has been reported to result in an inhibition 
of Pdh activity (33). As expected, hypoxia resulted 
in increased phosphorylation of the three analyzed 
serine residues (not significant in case of Ser300). 
However, and in line with low Pdk1 levels in 
normoxic M(LPS) macrophages, LPS activation 
did not increase phosphorylation levels of Ser 232 
and 293. Regarding Ser 300, we observed 
significantly increased phosphorylation upon LPS 
activation while there was no further significantly 
increased phosphorylation due to hypoxia. If 
Ser300 specifically has a unique function in the 
context of LPS activation in macrophages remains 
to be determined in future work. Our results from 
this part of the study reveal that Hif1 mediated 
induction of Pdk1 can be attenuated by LPS 
stimulation, which is in line with increased citrate 
M2 isotopologues upon LPS activation (Figure 
3B). 
In line with the results of Pdk1 abundance and Pdh 
phosphorylation status, our stable isotope analysis 
revealed that LPS stimulation did not result in a 
decreased relative pyruvate oxidation, both under 
hypoxia and normoxia (Figure 3B and I), 
indicating that Hif1 did not mediate Pdh inhibition 
upon LPS stimulation. We observed increased 
citrate M2 isotopologue levels, reflecting even 
higher relative pyruvate flux through Pdh (Figure 
3B). To normalize for upstream changes in 
glycolysis, we determined the ratio of M2 
citrate/M3 pyruvate and observed an increase upon 
LPS stimulation, indicating increased pyruvate 
flux through Pdh in M(LPS) macrophages (Figure 
3I). As a reduction of citrate M2 isotopologues 
was only observed under hypoxic conditions, Hif1 
mediated inhibition of Pdh depends only on the 
oxygen tension and not on the macrophage 
activation status. Indeed, LPS activation can even 
partially recover the Hif1 mediated Pdh inhibition 
under hypoxia (Figure 3B and I). 
The M2 abundance of aKG and malate were 
significantly lower than in citrate (Figure 3J and 
K), suggesting that large amounts of citrate, cis-
aconitate or isocitrate are either used for pathways 
other than the oxidative TCA cycle, or that other 
carbon sources (e.g. glutamine) increase their 
contribution to aKG and malate. Stimulation with 
LPS as well as hypoxia further decreased glucose 
contribution to aKG and malate, as can be seen by 
a decreasing abundance of aKG and malate M2 
isotopologues (Figure 3J and K). 
Next, we analyzed glucose uptake from the 
medium and cellular lactate release, to evaluate if 
M(LPS) macrophages increase their glycolytic 
rate. Under normoxia, LPS stimulated 
macrophages increased glucose uptake and lactate 
release whereas under hypoxia, glucose uptake 
and lactate release were exceeding the rate of 
M(LPS) macrophages under normoxia (Figure 
3L). This effect was further enhanced when 
hypoxic cells were additionally stimulated with 
LPS (Figure 3L). Under normoxia, the lactate to 
glucose ratio was increased from 1.2 to 1.6 upon 
LPS stimulation, indicating increased activity of 
LDH, which is in line with the Warburg-like 
phenotype of M(LPS) macrophages (3). However, 
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20% of the overall glucose carbon pool is still 
available for other metabolic pathways, indicating 
that M(LPS) macrophages still contain sufficient 
pyruvate to maintain oxidation through Pdh. 
It has been shown before that Stat3 specific 
signaling can inhibit Pdh and thus block pyruvate 
oxidation through Pdh in primary fibroblasts and 
cancer cell lines (35). Therefore we investigated if, 
and in contrast to LPS treatment, a Stat3 
dependent activation with the cytokine interferon-
γ (Infγ) might inhibit Pdh. To this end, we treated 
the cells with Infγ or LPS and analyzed the isotope 
enrichment in citrate. We did not observe a 
difference between LPS and Infγ treatment (Figure 
3M). In both cases, M2 citrate was significantly 
increased compared to untreated controls. In line 
with LPS activation we also observed decreased 
expression of Pdk1 in M(Infγ) macrophages 
(Figure 3N), indicating no inhibition of pyruvate 
oxidation in M(Infγ) macrophages. In conclusion, 
sustained pyruvate flux through Pdh and its 
regulation by Pdk1 seems to be independent of 
Tlr4 signalling. 
 
LPS activation increases glutamine uptake but 
does not induce reductive carboxylation of aKG  
It has been demonstrated that hypoxic cells 
metabolize increased amounts of glutamine via 
reverse IDH activity to generate citrate by 
reductive carboxylation of aKG (12–15) This 
pathway fuels the citrate pool to provide sufficient 
acetyl-coA for lipogenesis. Since M(LPS) 
activation also results in a stabilization of Hif1α 
(10,19,21,29) and increased glycolytic flux (see 
Figure 3I and L), we investigated if these cells 
exhibit increased reductive carboxylation of aKG. 
To that end, we applied a uniformly labeled [U-
13C]glutamine tracer and determined MIDs of 
TCA cycle metabolites (Figure 4A for atom 
transitions).  
As expected, under hypoxic conditions we 
observed a drop in oxidative TCA cycle activity 
and a strong induction of reductive carboxylation, 
inferred from decreased citrate M4 and increased 
citrate M5 isotopologues (Figure 4B-D). This 
pattern was also reflected by decreasing malate 
M4 (oxidative route) and increasing malate M3 
(reductive route) isotopologues (Figure 4E). 
However, when cells were stimulated with LPS at 
normoxic conditions, reductive carboxylation of 
aKG was not increased (Figure 4D).  
Using the glutamine tracer, we observed that the 
major carbon source of aKG was glutamine, and 
that upon LPS stimulation and under hypoxia, the 
abundance of M5 isotopologues increased, 
suggesting an increase in glutamine influx and a 
decreasing glucose contribution (Figure 4F). 
While hypoxia results in increased usage of aKG 
for reductive carboxylation and decreased aKG 
oxidation (14,15), we did not find evidence that 
LPS stimulation under normoxia compromises the 
relative glutamine carbon flux through aKG 
dehydrogenase, indicated by a similar enrichment 
pattern of aKG and malate.  
To analyze glutamine metabolism more in detail, 
we quantified glutamine uptake from the medium 
and glutamate release from the cells. While 
hypoxia did not result in increased glutamine 
uptake, we observed a strong increase of 
glutamine uptake upon LPS stimulation under both 
oxygen levels (Figure 4G). Since glutamate is 
produced from glutamine and can be released from 
the cell, we quantified glutamate release to infer 
glutamine anaplerosis to the TCA cycle. Although 
we observed increased glutamate release upon 
LPS stimulation, the net uptake of glutamine in 
LPS stimulated cells was still higher compared to 
untreated controls (ctrl: 12.84 vs LPS: 20.5 
fmol/cell/h) (Figure 4G and H). As indicated by 
the intracellular metabolite levels (Figure 1K), we 
also observed a trend of increased consumption of 
branched chain amino acids from the medium 
upon LPS stimulation (Figure 4I). However, these 
differences were only significant in the case of 
leucine. Nevertheless, we believe that the 
influence of branched chain amino acids on central 
metabolism is higher upon LPS activation. 
To better understand the impact of the different 
carbon sources to the TCA cycle metabolites, we 
calculated the carbon contributions of glucose and 
glutamine to citrate, aKG, malate and itaconate 
(Figure 4J). We observed a small decrease in 
glucose contribution to citrate upon LPS 
activation. However, based on the [U-13C]glucose 
derived MIDs, this decrease mostly originated 
from decreased citrate cycling through the 
oxidative TCA cycle (compare M3, M4 and M5 
isotopologues in Figure 3B) or increased 
 by guest on D
ecem
ber 23, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Pro-inflammatory macrophages sustain pyruvate oxidation 
9 
glutamine influx, rather than decreased pyruvate 
flux through Pdh (M2 isotopologue). Hypoxia 
resulted in a stronger reduction of glucose 
contribution to citrate, which was a result of Pdh 
inhibition. Along with the decrease in glucose 
contribution, the glutamine contribution to citrate 
was increased upon LPS, especially under 
hypoxia, where glutamine is the major carbon 
source of citrate. For aKG and malate, the glucose 
contribution was significantly lower compared to 
citrate, indicating that major parts of the citrate 
pool are not used for further oxidation through the 
oxidative TCA cycle, but for anabolic processes 
such as lipid synthesis or itaconate synthesis. In 
line with this observation we observed higher 
glucose contribution to itaconate, compared to 
aKG and malate. Moreover, upon LPS stimulation, 
and especially with hypoxia, we observed an 
increase of other carbon sources than glucose or 
glutamine, which is in line with potentially 
increased uptake of branched chain amino acids 
(Figure 1K and 4I). 
In summary, we observed that glutamine is the 
major carbon source of the TCA cycle in M(LPS) 
macrophages and is the main substrate for TCA 
oxidation. Glucose carbon still enters the cycle at 
citrate, however significant amounts of the citrate 
pool are not further oxidized through IDH but are 
distributed to other metabolic pathways. 
Glutamine serves to replenish this lack of carbon 
by increased uptake upon LPS stimulation. 
 
LPS causes an increase in lipogenesis in 
RAW264 cells 
Besides transcriptional and metabolic adaptations 
to inflammation, it has been described that pro-
inflammatory macrophages also undergo 
morphological changes from small and spherical 
to a larger and more attached form (Figure 5A). To 
demonstrate the surface enlargement during LPS 
activation, we monitored cell size by using two 
orthogonal microscopy approaches (Figure 5B), 
demonstrating an increase in cell surface and thus 
pointing to an increased demand on lipids needed 
for membrane formation. Furthermore, M(LPS) 
macrophages increase intracellular and 
extracellular vesicle formation during pathogen 
defense (36). Therefore, M(LPS) macrophages 
have an increased demand for lipids, needed for 
morphological changes and vesicle formation. To 
meet this demand, LPS activated macrophages 
need to prioritize their metabolism towards 
lipogenesis and to repress lipid oxidation. In line 
with this necessary metabolic shift, we observed 
decreased expression of carnitine 
palmitoyltransferase 1 (Cpt1), which imports 
palmitate into the mitochondrion for lipid 
oxidation and subsequent energy production 
(Figure 5C). A reduction of ß-oxidation is in line 
with reports of decreased oxidative metabolism in 
M(LPS) macrophages (37) and supports the 
observed increased demand for lipids. High 
activity of lipid degradation, simultaneously to 
their synthesis, would be a waste of energy. 
To generate lipids from central metabolism, cells 
export mitochondrial citrate into the cytoplasm 
where it is hydrolyzed via ATP dependent citrate 
lyase (Acly) to provide acetyl-coA for lipogenesis. 
In this preferred case, citrate utilization is for 
anabolic processes rather than the TCA cycle. To 
analyze the contribution of glucose and glutamine 
to palmitate, an endpoint of fatty acid synthesis, 
we determined the MIDs of - and carbon 
contributions to - palmitate after both the 
application of [U-13C]glucose and [U-
13C]glutamine as tracers in independent 
experiments (Figure 5D and E). We observed that 
under normoxia, nearly 50% of the carbon in 
palmitate originated from glucose. Under hypoxic 
conditions, a shift in isotopologues indicated that 
the glucose contribution was reduced while 
glutamine contribution was increased, suggesting 
increased reductive carboxylation under hypoxia, 
but not as a result of LPS stimulation. Although 
dependent on the pool sizes of the metabolites, 
increased production of itaconate and palmitate 
from glucose derived citrate in M(LPS) 
macrophages indicates reduced citrate oxidation 
through the TCA cycle in M(LPS) macrophages. 
  
Pyruvate flux to citrate is important for LPS 
activation in RAW264 cells 
To investigate the importance of the Pdh flux in 
M(LPS) macrophages, we used a pharmacological 
approach to impair pyruvate oxidation through 
Pdh by inhibiting the pyruvate transporter with the 
specific inhibitor UK5099 (38). Using this 
inhibitor together with the [U-13C]glucose tracer, 
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we observed a significant decrease of citrate M2 
isotopologues, indicating reduced relative 
pyruvate oxidation through Pdh (Figure 6A). 
Addition of LPS to UK5099 treated cells could not 
restore the abundance of M2 citrate, since 
pyruvate supply is impaired by the inhibition of 
the transporter. Analysis of intracellular metabolite 
levels revealed that inhibition of pyruvate 
transport into the mitochondrion resulted in 
decreased amounts of citrate, originating from 
reduced substrate levels for citrate synthase 
(Figure 6B). Intriguingly, we also observed 
decreased amounts of the inflammatory marker 
metabolites itaconate and succinate under pro-
inflammatory conditions (Figure 6C and D). 
Decreased amounts of itaconate and succinate 
could either result from decreased glucose flux 
into the TCA cycle, similar to hypoxia, or from a 
metabolic alteration in M(LPS) macrophages. To 
analyze these hypotheses, we investigated the gene 
expression profiles of pro-inflammatory marker 
genes (Figure 6E-H). While, Il1b gene expression 
was not significantly decreased (Figure 6E), we 
observed that UK5099 treatment of LPS 
stimulated macrophages resulted in decreased 
expression levels of iNos, Irg1 and Tnfα (Figure 
6F-H), indicating that in this case and in contrast 
to hypoxia, the observed decreased itaconate level 
roots back to decreased Irg1 levels. Moreover, 
application of UK5099 to LPS stimulated cells 
resulted in increased Cpt1 expression levels, 
similar to untreated controls, while Pdk1 
expression was still reduced, due to the fact that 
pyruvate import into the mitochondrion was 
inhibited, and thus regulation of Pdh not necessary 
(Figure 6I and J). To exclude a potential toxic 
effect of UK5099 on RAW264 cells, we 
performed a viability assay and did not observe 
significant changes in viability (Figure 6K). To 
further exclude the possibility of timing effects 
due to simultaneous addition of LPS and UK5099, 
we repeated the experiments with a modified 
experimental setup, where we first activated the 
cells with LPS for 3h and added then UK5099 for 
additional 6h to investigate if this intervention can 
repress the pro-inflammatory profile of M(LPS) 
macrophages (Figure 6L). Following this approach 
we also observed significantly decreased citrate, 
itaconate and succinate levels (Figure 6M-O) and 
significantly decreased expression of Tnfα, iNos, 
Irg1 and Il1b (Figure 6P-S). These results indicate 
that inhibition of pyruvate import into the 
mitochondrion can indeed supress pro-
inflammatory responses in M(LPS) macrophages. 
Finally, we investigated the effect of carbon 
contribution to palmitate for these conditions, 
using [U-13C]glucose as a tracer, in combination 
with UK5099. In line with decreased citrate, 
itaconate and succinate levels upon UK5099 
treatment, we also observed lower carbon 
contribution from glucose to palmitate (Figure T 
and U). 
In summary, these data demonstrate that the 
pyruvate flux through Pdh is important for LPS 
activation in macrophages. Apparently, altered 
metabolic fluxes or changes in metabolite 
concentrations enable a feedback mechanism to 
regulate cellular gene expression profiles. Hence, 
metabolic intervention can be used to attenuate 
activation of M(LPS) macrophages. 
 
DISCUSSION 
M(LPS) macrophages require extensive 
reprogramming to enable host defense 
mechanisms. While M(IL4) macrophages increase 
oxidative metabolism optimized for tissue repair 
(39), M(LPS) macrophages develop a Warburg-
like phenotype by increasing glycolysis and lactate 
release (3). It has been demonstrated that pro-
inflammatory activation results in the stabilization 
of Hif1α, Hif1 complex formation with 
monomeric or dimeric PKM2, along with an 
increased expression of M(LPS) associated 
cytokines and bacterial defense mechanisms (29). 
Since, under hypoxia, Hif1 not only increases the 
glycolytic activity, but also represses Pdh activity 
through Pdk1, it was speculated that glucose flux 
through Pdh is also repressed in M(LPS) 
macrophages (3,40). However, this would 
withdraw carbon supply, necessary for lipogenesis 
and synthesis of the antimicrobial metabolite 
itaconate. 
In this work, we demonstrate that the Pdh flux 
plays an important role in maintaining full LPS 
specific activation and that pharmacological 
intervention to prevent pyruvate oxidation 
represses pro-inflammatory activation. Although 
an active Pdh flux has been speculated for early 
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macrophage differentiation and for dendritic cells 
before (3,41), our results demonstrate that 
pyruvate oxidation through Pdh is fully active in 
mature M(LPS) macrophages and that this is even 
essential to sustain LPS activation. Moreover, we 
discovered that this process is facilitated by 
repressed Pdk1 expression and no increase in Pdk1 
protein abundance, as well as significantly lower 
phosphorylation of Pdh compared to hypoxic 
conditions, illustrating that M(LPS) macrophages 
sustain an active pyruvate flux through Pdh. 
Under hypoxia, Hif1 decreases pyruvate oxidation 
through Pdh by inducing Pdk1 (32). In contrast to 
hypoxia, we demonstrated that although glycolysis 
is increased and oxygen consumption is decreased 
(29) in M(LPS) macrophages, pyruvate oxidation 
through Pdh is not inhibited, because Pdk1 
abundance is not increased. Active Pdh facilitates 
a stable citrate pool, which in turn prevents 
increased reductive carboxylation of aKG by 
thermodynamic means (16). M(LPS) macrophages 
have been shown to increase their expression of 
the mitochondrial citrate carrier to transport citrate 
from the mitochondrion into the cytosol (42) and 
we have shown that M(LPS) macrophages have an 
increased lipid demand. Since we demonstrated 
that reductive carboxylation of aKG is not 
increased, the high demand of citrate has to be 
mostly supplied by glucose through Pdh.  
When Pdh flux is repressed, citrate is increasingly 
generated by reductive carboxylation of aKG, 
which is mostly derived from glutamine (43). An 
increased demand on glutamine in M(LPS) 
macrophages has been reported before (44). Here 
we describe in detail how this glutamine is 
utilized. In M(LPS) macrophages most glutamine 
is preferentially used for glutaminolysis rather 
than for reductive carboxylation of aKG. Besides 
Acly derived oxaloacetate, increased 
glutaminolysis additionally provides oxaloacetate, 
which is needed as an acceptor for pyruvate 
derived acetyl-coA and the synthesis of citrate. It 
also replenishes the TCA cycle to compensate for 
increased lipogenesis and the loss of carbon that is 
used for the synthesis of itaconate.  
It is known that LPS activation results in 
decreased oxygen consumption, which suggests 
that TCA cycle activity is decreased and would 
provide less NADH to be oxidized via the ETC 
(29,45,46). However, we found evidence that the 
oxidative TCA cycle is still running and is fueled 
by increased amounts of glutamine. TCA cycle 
derived NADH can be used for alternative routes 
and would consequently not be oxidized via the 
ETC and thus, also result in reduced oxygen 
consumption rates. Mitochondrial derived NADH 
can alternatively be converted to NADPH by 
nicotinamide nucleotide transhydrogenase (17,47), 
which is utilized by M(LPS) macrophages for 
ROS production via NADPH oxidase, needed for 
antibacterial activity (48), or transferred to the 
cytoplasm (49) where it is needed for lipogenesis. 
Therefore it is possible that M(LPS) macrophages 
use increased amounts of TCA cycle derived 
NADH for the generation of NADPH rather than 
oxidizing it via the ETC, which fits to the reported 
decreased oxygen consumption rates (6,45,46). 
Additionally, the ETC can be directly inhibited by 
nitrosylation (50,51) promoted by increased 
expression of iNos, which we have shown to be 
increased upon LPS stimulation. Therefore, 
decreased oxygen consumption in M(LPS) 
macrophages due to decreased ETC activity is 
reasonable, but a decreased ETC activity does not 
necessarily have to result in decreased oxidative 
TCA cycle activity. 
Although we could demonstrate that Pdh activity 
is important in M(LPS) macrophages, the 
mechanism of how Pdk1 repression is facilitated 
despite the presence of Hif1 needs additional 
research. One possibility would be a weaker 
stabilization because Hif1α is not as abundant as 
in hypoxic cells. However, in this case we would 
still expect a similar mode of action, and therefore, 
a moderate induction of Pdk1. LPS activation 
exhibits distinct regulatory modules (2) and we 
conclude that these specific networks overlap with 
the classical Hif1 signature to mediate LPS 
specific activation. Since we demonstrated that 
M(LPS) macrophages depend on the Pdh flux to 
induce cytokine expression and synthesis of 
itaconate, it appears that a specific Hif1 induced 
upstream regulator exists which specifically 
prevents Pdk1 expression. In this way, increased 
glucose uptake and lactate release can still be 
facilitated by Hif1, whereas Pdk1 activity is 
prevented by an additional regulator. Overall, this 
points towards a context-dependent Hif1 response.  
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With the hypoxia model, we demonstrated that the 
decreased pyruvate flux through Pdh results in 
decreased levels of the antimicrobial metabolite 
itaconate as well as decreased levels of succinate. 
However, gene expression of Irg1 was unchanged. 
We conclude that, under hypoxia, decreased 
metabolite levels are a passive effect of decreased 
pyruvate oxidation and decreased oxidative 
mitochondrial metabolism. This also illustrates 
that Hif1 mediated inhibition of Pdh would be 
disadvantageous to M(LPS) macrophages and that 
parts of the TCA cycle are indeed important for 
M(LPS) macrophages e.g. for the synthesis of 
lipids and itaconate.  
By inhibiting the pyruvate import into the 
mitochondria of M(LPS) macrophages, we 
observed decreased metabolite levels of itaconate 
and succinate, similar to hypoxia. Intriguingly, in 
the case of transport inhibition, gene expression of 
Irg1, Tnfα and iNos were decreased as well. All of 
these genes are hallmarks of LPS activation, 
indicating a general impairment of activation in 
matured M(LPS) macrophages.  
Based on our observations we can now extend the 
existing metabolic model of M(LPS) macrophages 
(Figure 7): (1) We confirmed the findings of 
increased glycolysis and increased lactate release, 
(2) Furthermore, reductive carboxylation of aKG 
is not increased in M(LPS) macrophages, but 
instead glutamine is still oxidized through aKG 
dehydrogenase, (3) Lastly, pyruvate is still 
oxidized through Pdh, which turned out to be 
essential for full LPS activation. Our work 
revealed a LPS specific metabolic feature that is 
essential for activation and that might be 
approached by further studies in the light of 
translational medicine, to develop novel therapies 
against inflammatory dysfunctions. 
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FIGURE 1. Metabolome analysis of RAW264 macrophages in the context of LPS activation and 
hypoxia. Analysis of intracellular metabolite abundance in RAW264 cells, cultivated under normoxia 
(21% O2) and hypoxia (2% O2), unstimulated or stimulated with LPS. Metabolites were extracted and 
analyzed by GC/MS. Signal intensities (peak area) are normalized to unstimulated cells under normoxia. 
Cells were treated with 10 ng/ml LPS for 6 hours. Error bars indicate SEM (Welsh's t-Test, * p < 0.01, n 
= 3 wells). One representative experiment with three individual wells per condition is presented. The 
experiment was performed three times. 
FIGURE 2. Expression analysis of pro-inflammatory associated genes. (A) Relative gene expression 
of Irg1. (B) Western blot against Irg1/Cad, the protein that catalyzes the conversion of cis-aconitate to 
itaconate (no significant difference (data not shown)). (C-F) Relative gene expression of Tnfα, iNos, Il1ß 
and Hif1α, normalized to normoxia Ctrl (-LPS). Error bars indicate SEM (Welsh's t-Test, * p < 0.01, n = 
3). Gene expression data represents the mean over three independent experiments. 
 
FIGURE 3. Pdh flux analysis in M(LPS) macrophages. (A) Schematic of atom transitions in central 
metabolism using [U-13C]glucose as a tracer for determination of mass isotopomer distributions (MIDs) 
to infer relative intracellular fluxes. 13C carbons are in grey, 12C in black. The dotted line indicates end of 
one route. Aco: aconitase; Idh: isocitrate dehydrogenase; Akgdh: aKG dehydrogenase; OA: oxaloacetate. 
(B) MID of citrate. M0 – M6 indicates the different mass isotopologues. (C) gene expression analysis of 
Pdk1. (D-H) Western Blot analysis of Pdk1 and Pdh phosphorylation on Ser232, 293 and 300. α-Tubulin 
serves as loading control. (D) shows one representative western Blot of three independent experiments. 
(E-H) shows quantification of three independent experiments. (I) Ratio of M2 citrate/M3 pyruvate 
indicating relative pyruvate oxidation through Pdh. (J-K) MID of aKG and Malate. (L) Absolute 
quantification of glucose uptake and lactate release, and ratio of lactate release/glucose uptake to infer 
fractional lactate formation per glucose. (M) Activation of RAW264 cells with 10 ng/ml LPS or 50 ng/ml 
interferon-γ (Inf) in medium with [U-13C]glucose. Presented are citrate M2 isotopologues as a readout for 
relative glucose flux through Pdh. (N) Relative gene expression of Pdk1 normalized to normoxia Ctrl (-
LPS). Error bars indicate SEM. (Welsh's t-Test, * p < 0.01, n = 3). One representative experiment with 
three individual wells per condition is presented. Each experiment was performed at least three times, 
except for (C): Presented is the mean +/-SEM over three independent experiments. (Welsh's t-Test, * p < 
0.01, n = 3) 
 
FIGURE 4. Contribution of glutamine to central metabolism in M(LPS) macrophages. (A) 
Schematic of atom transitions in central metabolism using [U-13C]glutamine as a tracer. 13C carbons are in 
grey, 12C in black. Citrate molecules derived from reductive carboxylation of aKG are M5 isotopologues, 
whereas citrate molecules from the oxidative route of the TCA cycle are M4 isotopologues. The dotted 
line indicates end of one route. Aco: aconitase; Idh: isocitrate dehydrogenase; Akgdh: aKG 
dehydrogenase; Acly: ATP dependent citrate lyase; FA: Fatty acid. (B) MID of citrate. M0 – M6 indicates 
the different mass isotopologues. (C-D) Determination of oxidative TCA cycle activity: ratio of M4 
citrate/M5 glutamate and Ratio of M5 citrate/M5 glutamate indicating relative reductive Idh flux. (E-F) 
MID of malate and aKG (G-I) Absolute quantification of glutamine uptake, glutamate release and uptake 
of the branched chain amino acids (valine, isoleucine and leucine). (J) Carbon contribution (%) of 
glucose, glutamine and other carbon sources to citrate, aKG, malate and itaconate. Carbon contributions 
are based on MIDs from [U-13C]glucose labeling (Figure 3) and [U-13C]glutamine labeling. Carbon 
contribution to itaconate under non-LPS conditions should not be considered since itaconate levels are 
negligible low under these non-stimulated conditions (Figure 1A). Error bars indicate SEM (Welsh's t-
Test, * p < 0.01, n = 3). One representative experiment with three individual wells per condition is 
presented. Each experiment was performed at least three times. 
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FIGURE 5. Morphological changes upon LPS activation require sustained lipogenesis in 
macrophages. (A) Microscopy (brightfield image) of RAW macrophages unstimulated or stimulated 
with 10 ng/ml LPS for 6h. White bar indicates 100 µm (B) Mean average of cell size [pixels] (left) and 
analysis of adhesion index (right) of LPS stimulated and non-stimulated cells, obtained from brightfield 
microscopy. Analysis demonstrates morphological adaption of macrophages during LPS activation. For 
further details regarding the analysis approach see experimental procedures. (C) Relative gene expression 
of carnitine palmitoyl transferase1 (Cpt1) normalized to normoxia Ctrl (-LPS), indicating inhibition of ß-
oxidation upon LPS stimulation. (D-E) MID of palmitate using (D) [U-13C]glucose and (E) [U-
13C]glutamine as a tracer. Contribution of each carbon source is depicted in the top right corner of each 
panel. Error bars indicate SEM (Welsh's t-Test, * p < 0.01, n  ≥ 3). One representative experiment with 
three individual wells per condition is presented. Each experiment was performed at least three times; 
except for (C): Presented is the mean +/-SEM over three independent experiments. (Welsh's t-Test, * p < 
0.01, n = 3). 
 
FIGURE 6. Inhibition of pyruvate transport into mitochondria suppresses pro-inflammatory 
responses in M(LPS) macrophages. (A) Application of the specific pyruvate transport inhibitor UK5099 
to inhibit flux through Pdh. Cells were treated with 100 µM UK5099 for 6h with or without 10 ng/ml LPS 
at normoxia. Prior to treatment start, cells were cultivated for 24h in [U-13C]glucose. Presented are citrate 
M2 isotopologues as a readout for relative glucose flux through Pdh. (B-D) Intracellular metabolite levels 
of citrate, itaconate and succinate upon LPS stimulation and after application of 100 µM UK5099. 
Metabolite levels were determined using GC/MS and normalized to cell number. (E-J) Relative gene 
expression of Il1ß, iNos, Irg1, Tnfα, Cpt1 and Pdk1 normalized to normoxia Ctrl (-LPS), upon LPS 
stimulation and after application of 100 µM UK5099 for 6h. (K) Viability assay to test a potential effect 
of UK5099 on cell viability. Assay was performed using Trypan blue, dead and live cells were counted. 
(L) To validate the effect of UK5099 a modified experimental setup has additionally been performed. 
Cells were first activated with 10ng/ml LPS for 3h and then UK5099 was added to the cells for additional 
6h. In total, LPS activation was 9h in this case. Non-UK5099 treated and non-activated cells served as 
control. (M-O) Intracellular metabolite levels for citrate, itaconate and succinate (analysis as in (B-D)). 
(P-S) Relative gene expression analysis of  Tnfα , iNos, Irg1 and Il1ß. (T-U) MID of Palmitate using [U-
13C]glucose as a tracer. Experimental setup as in (A). (U) Glucose contribution to palmitate, determined 
from (T). Error bars indicate SEM (Welsh's t-Test, * p < 0.01, n = 3). One representative experiment with 
three individual wells per condition is presented. Each experiment was performed at least three times. 
 
FIGURE 7. Model summarizing the metabolic adaptations in M(LPS) macrophages. Resting cells 
use glucose via Pdh and TCA oxidation for energy production. Depending on the cell type, anabolic 
processes run in parallel. Hypoxic cells and cancer cells with stabilized Hif1α, increase their glycolytic 
rate, inhibit Pdh flux and use glutamine derived carbon for increased reductive carboxylation of aKG for 
subsequent lipogenesis. Highly proliferating cells promote anabolic processes to support proliferation. 
M(LPS) macrophages show stabilized Hif1α but do not decrease pyruvate oxidation through Pdh. Under 
this condition Hif1α does not increase PDk1 abundance. Compared to resting cells, less citrate is oxidized 
through the TCA cycle and is rerouted to serve as a precursor for itaconate and fatty acid synthesis. 
Glutamine serves to replenish the TCA cycle by increasing its carbon contribution to aKG and subsequent 
metabolites. BCAAs might also support carbon supply to the TCA cycle but this needs additional 
research. Despite sustained pyruvate oxidation through Pdh, oxygen consumption rates are lower than in 
resting cells. 
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TABLE1. Primer sequences used for qPCR 
 
 Gene 5' – 3' sequence
L27_F ACATTGACGATGGCACCTC
L27_R GCTTGGCGATCTTCTTCTTG
IRG1_F GCAACATGATGCTCAAGTCTG
IRG1_R TGCTCCTCCGAATGATACCA
TNFa_F GGTTCTGTCCCTTTCACTCAC
TNFa_R TGCCTCTTCTGCCAGTTCC
iNOS_F AGCCCTCACCTACTTCCTG
iNOS_R CAATCTCTGCCTATCCGTCTC
PDK1_F TGCAAAGTTGGTATATCCAAAGCC
PDK1_R ACCCCGAAGCTCTCCTTGTA
IL1b_F TGCCACCTTTTGACAGTGATG
IL1b_R TGATGTGCTGCTGCGAGATT
CPT1_F TGGCAGTCGACTCACCTTTC
CPT1_R CAAACAGTTCCACCTGCTGC
HIF1a_F TGACGGCGACATGGTTTACA
HIF1a_R AATATGGCCCGTGCAGTGAA
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FIGURE 1 
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FIGURE 2 
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FIGURE 3 
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FIGURE 4 
 
[U-13C]glutamine
Citrate
TCA cycle Isocitrate
α-KG
Malate
Succinate
Itaconate
Acetyl-CoA
OAA Malate
Acetyl-CoA
FA
Citrate
0.1
0.2
0.3
0.4
0.5
M0 M1 M2 M3 M4 M5 M6
 LPS  - + +- - + +- - + +- - + +- - + +- - + +- - + +-
Normoxia
Hypoxia
R
el
at
iv
e 
ab
un
da
nc
e
fro
m
 
[U
-1
3 C
]g
lu
ta
m
in
e
B
E F
A
LPS
Normoxia   Hypoxia
+- +-
10
20
30
40
50
Glutamine uptake
fm
ol
/c
el
l/h
G
Normoxia   Hypoxia
+- +-
4
8
12
16
Glutamate release
Normoxia        Hypoxia
+- +-
Itaconate
27 11
59 64
14 25
J
C
*
*
*
*
0.2
0.4
0.6
0.8
M0 M1 M2 M3 M4 M5
 LPS  - + +- - + +- - + +- - + +- - + +- - + +-
Normoxia
Hypoxia
aKG
R
el
at
iv
e 
ab
un
da
nc
e 
fro
m
 
[U
-1
3 C
]g
lu
ta
m
in
e *
*
*
** *
Malate
Normoxia
Hypoxia
M0 M1 M2 M3 M4
 LPS  - + +- - + +- - + +- - + +- - + +-
0.1
0.2
0.3
0.4
0.5
0.6
R
el
at
iv
e 
ab
un
da
nc
e 
fro
m
 
[U
-1
3 C
]g
lu
ta
m
in
e
* *
*
*
*
*
I
2
4
6
8
10
12
BCAAs uptake
Valine
Isoleucine
Leucine
fm
ol
/c
el
l/h
LPS
Normoxia               Hypoxia
+- +-
p = 0.04
*
*
*
*
0.2
0.4
0.6
M
5 
ci
tra
te
/M
5 
gl
ut
am
at
e
n.s.
* *
Relative reductive 
Idh flux
M
4 
ci
tra
te
/M
5 
gl
ut
am
at
e
0.2
0.4
0.6
0.8
LPS
Normoxia  Hypoxia
+- +-
* *
Relative oxidative 
TCA cycle activity
%
 C
on
tri
bu
tio
n
Citrate
20
40
60
80
100
44 38 19 18
46
49
58 60
11 14 23 22
LPS
Normoxia        Hypoxia
+- +-
aKG
26 17 11 6
71
78
82 88
Normoxia        Hypoxia
+- +-
Unknown
Glutamine
Glucose Malate
29 19 10 6
63
71
68 72
8 10 22 22
Normoxia        Hypoxia
+- +-
H
fm
ol
/c
el
l/h
CO2
CO2
Idh
Akgdh
Aco
Irg1
Acly
LPS
Normoxia  Hypoxia
+- +-
D
p = 0.04
 by guest on D
ecem
ber 23, 2015
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
Pro-inflammatory macrophages sustain pyruvate oxidation 
24 
FIGURE 5
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FIGURE6 
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FIGURE7 
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